ADNI PiB Amyloid Imaging Chet Mathis University of Pittsburgh.

Slides:



Advertisements
Similar presentations
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D2 – AD brain scans – metabolism - PET NUCLEAR MEDICINE.
Advertisements

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.
Department of Neurology, Mayo Clinic Arizona
December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.
Variability of PET-PIB retention measurements due to different scanner performance in multi-site trials Jean-Claude Rwigema Chet Mathis Charles Laymon.
Ethics in Alzheimer's Disease: New diagnostic criteria, new biomarkers, new challenges Steven T. DeKosky, MD James Carroll Flippin Professor of Medical.
MemTrax (Computerized Memory Screen) American Association of Geriatric Psychiatry (AAGP) March 2, 2007 J. Wesson Ashford, M.D., Ph.D. Stanford / VA Aging.
©2011 MFMER | slide-1 Alzheimer Disease: Update Neill R. Graff-Radford, MBBCh, FRCP Professor of Neurology Mayo College of Medicine.
Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
Significance of White Matter Hyperintensities in MCI Charles DeCarli University of California at Davis Alzheimer’s Disease Center Imaging of Dementia and.
BERG SYMPOSIUM WASHINGTON UNIVERSITY SEPT 2003 MICHAEL W WEINER MD.
Mary Ganguli’s Slides March 13 th Meeting. Mild Cognitive Impairment A View from the Trenches.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
TEMPLATE DESIGN © All PET scans were processed to uniform resolution as implemented by ADNI (Joshi, 2009) to minimize.
Risk of Developing Alzheimer’s Disease in Persons with MCI
Mapping the correlations between CSF Abeta and tau and hippocampal atrophy in 282 ADNI subjects Liana G. Apostolova, Amity E. Green, Kristy S. Hwang, Jonathan.
The best of both worlds Pharma R&D IT - Informatics Rudi Verbeeck Guided analytics in the hands of the SME.
Mild Cognitive Impairment
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.
Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.
conflicts of interest to report.
PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.
Clifford R Jack Jr MD Professor of Radiology
Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital.
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Mechanism of Amyloid Removal in Patients With Alzheimer.
CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS
Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of Short- term conversion to AD: Results from ADNI Xuejiao.
DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)
Update of China-ADNI Kuncheng Li, MD. PhD.
INDIA - ADNI Dr Naren Rao
Rosa Maria Moresco University of Milan Bicocca
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Presenter: Dr. Patricio Chrem
Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;
Imaging AD Progression Amyloid Imaging Agents.
INDIA - ADNI Dr Naren Rao
ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue
Presenter: Dr. Patricio Chrem
Update of China-ADNI Kuncheng Li, MD. PhD.
Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W
Chris Hyde Exeter Test Group.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Boston Naming Test predicts deterioration of cerebrospinal fluid biomarkers in pre-symptomatic Alzheimer’s disease Charleen Wilder, MA, Kristina Moncrieffe,
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.
Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.
Figure 1 [18F]florbetapir standardized uptake value ratio analytical method [18F]florbetapir standardized uptake value ratio analytical method Flowchart.
ADNI 3 UPDATE MICHAEL WEINER.
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.
Fig. 2. Correlation between Aβ42 and Aβ40 levels in iNPH, AD, and CN subjects. The scatter plot shows the correlation between Aβ42 and Aβ40 levels. Representative.
Figure 3 Changing appearance of the frontal cortex with age associated with increasing myelination Changing appearance of the frontal cortex with age associated.
Figure 2 Aβ-PET scans obtained using different tracers
ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;
Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;
Presentation transcript:

ADNI PiB Amyloid Imaging Chet Mathis University of Pittsburgh

Enrollment in ADNI PiB Studies to June 2010 ( All Data Are Available On The LONI Website) Baseline – 103 Subjects at 14 PET Sites NL: 19, 78±5 y/o, MMSE 29±1 MCI: 65, 75±8 y/o, MMSE 27±2 AD: 19, 73±9 y/o, MMSE 22±3 1 Yr Longitudinal Studies – 80 Subjects NL: 17/19 (89%) MCI: 50/65 (77%) AD: 13/19 (68%) PiB Baseline Entry Times 20 subjects at ADNI true baseline 69 subjects at ADNI 12 months 14 subjects at ADNI 24 months 3 Yr Longitudinal Studies – 2 Subjects NL: 2 MCI: 0 AD: 0 2 Yr Longitudinal Studies – 39 Subjects NL: 11 MCI: 26 AD: 2 Total 224 PiB Scans

Baseline PiB Studies: 103 Subjects (19 NL, 65 MCI, 19 AD)

SUVR ACGFC PAR PRC NeoC4 Ave Baseline ADNI PiB Subjects NL MCI AD Cut-Off: Aizenstein et al., Arch Neurol 2008; 65: Cut-off PiB(+)

SUVR NLMCI AD PiB(-) PiB(+) PiB NeoC4 SUVR Baseline Values by Subject Group n =

1 Year Longitudinal PiB Follow-Up Studies: 80 Subjects (17 NL, 50 MCI, 13 AD)

1 Year Changes in PiB NeoC4 SUVR Values by Subject Group Baseline 1 year Baseline 1 year N =

2 Year Changes in PiB NeoC4 SUVR Values by Subject Group N = Baseline 2 year Baseline 2 year

Logan DVR Baseline 1 Yr 2 Yr Longitudinal PiB Studies Cognitively Normal Elderly Subject

PiB NeoC4 Reliable Change Index (RCI) Defined Using Test-Retest Scans 0% 5% 10% 15% 20% 25% 30% / Delta SUVR Frequency  (one-tailed) p=0.05 >0.215  -SUVR

ADNI PiB Longitudinal RCI Data PiB(-) PiB(+) Ctrl # >0.215 MCI # >0.215 AD # >0.215 All PiB(-) 2/26 = 8% All PiB(+) 11/54 = 20% 1 Yr Significant PiB NeoC4 RCI Changes

ADNI PiB Longitudinal RCI Data PiB(-) PiB(+) Ctrl # >0.215 MCI # >0.215 AD # >0.215 All PiB(-) 0/17 = 0% All PiB(+) 4/22 = 18% 2 Yr Significant PiB NeoC4 RCI Changes

Mild Cognitive Impairment: Predictive Value of PiB Scanning

Lopresti et al., J Nuclear Medicine 2005 MCI’s Cover the Range of Amyloid Load

Does PiB-Positivity Predict Clinical Conversion of MCI to AD? Three Published Studies To Date: Forsberg et al., Neurobiol Aging 2008 Wolk et al., Annals of Neurology 2009 Okello et al., Neurology 2009 Over 1-2 Years of Follow-Up PiB(+) MCI  AD Converters: 26/44 (59%) PiB(-) MCI  AD Converters: 1/21 (5%)

Does PiB-Positivity Predict Clinical Conversion of MCI to AD? ADNI PiB MCI Conversion Data Over 1-2 Years of Follow-Up PiB(+) MCI  AD Converters: 21/47 (45%) PiB(-) MCI  AD Converters: 3/18 (16%)

PiB NeoC4 SUVR: PiB(+) ADNI PiB Converters from MCI to AD PiB(-) PiB NeoC4 SUVR: “abnormal FDG scan with an FTD-like pattern” “severely abnormal FDG scan with an FTD-like pattern; highly confident of FTD” “not clearly abnormal, although borderline abnormalities are limited to frontal regions”

Use of Pons as Reference Region

SUVR ACGFC PAR PRC NeoC4 Ave Baseline ADNI PiB Subjects (PONS) NL MCI AD Cut-off PiB(+)

SUVR ACGFC PAR PRC NeoC4 Ave Baseline ADNI PiB Subjects NL MCI AD Cut-Off: Aizenstein et al., Arch Neurol 2008; 65: Cut-off PiB(+)

ADNI PiB Summary Results from baseline ADNI PiB scans are generally consistent with other groups and the literature Year 1 and 2 longitudinal PiB scans show small or no group increases, but ~20% of individual PiB(+) subjects show significant increases over 1-2 year ADNI PiB MCI to AD conversion data show ~3X as many PiB(+) conversions than PiB(-) conversions. More ADNI PiB(-) converted compared to literature data, but the n is low for ADNI and 2 of 3 PiB(-) subjects had an FDG pattern consistent with FTD not AD Use of Pons as the reference region made little difference in data analysis results and interpretation ADNI PiB data contain more noise than data collected at one site, but provide a useful, open database for investigators

Acknowledgements ADNI PiB Funding Alzheimer’s Association GEHC Collaborators Bill Jagust, UC Berkeley Bob Koeppe, U Michigan Norm Foster, U Utah Bill Klunk, U Pittsburgh Julie Price, U Pittsburgh

Reliable Change Index (RCI) Jacobson & Truax, J Consult Clin Psychol 59:12-19 (1991) Compares the change in an individual over time to “noise” measured in test-retest experiments Noise = SD diff = RCI = (SUVR t2 – SUVR t1 ) / SD diff (i.e., a z-score) Significant at p=0.05 when RCI >  (one-tailed because interested in significant increases)

PiB Reliable Change Index (RCI) Defined at Pittsburgh [Retest –Test] PiB value determined for: 7 Control, 9 MCI, and 6 AD subjects within 28 days Values did not differ by diagnostic group, so all 22 subjects were combined SD diff was calculated for each individual ROI and NeoC4 average RCI then calculated for each subject at 1 or 2 years

ADNI PiB Longitudinal RCI Data (PONS) PiB(-) PiB(+) Ctrl # >0.114 MCI # >0.114 AD # >0.114 All PiB(-) 0/27 = 0% All PiB(+) 10/53 = 19% 1 Yr Significant PiB NeoC4 RCI Changes

ADNI PiB Longitudinal RCI Data (PONS) PiB(-) PiB(+) Ctrl # >0.114 MCI # >0.114 AD # >0.114 All PiB(-) 0/17 = 0% All PiB(+) 4/22 = 18% 2 Yr Significant PiB NeoC4 RCI Changes